Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.53 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047483 | 0.92 | EDNRA (0.54) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7048930 | 0.90 | EDNRA (0.53) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7046286 | 0.89 | EDNRA (0.68) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7048779 | 0.89 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL7047487 | 0.88 | EDNRA (0.48) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7046595 | 0.87 | EDNRA (0.59) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7050175 | 0.85 | EDNRA (0.47) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7046657 | 0.85 | EDNRA (0.47) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7045934 | 0.84 | EDNRA (0.55) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7047806 | 0.80 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | claimed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | claimed |
| US-6420567-B1 | PRODRUGS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-07-16 | — | — | US | claimed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | claimed |
| EP-0946552-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | claimed |
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2003-11-06 | — | — | US | disclosed |
| US-6632829-B2 | Thienyl, furyl and pyrrolyl-sulfonamides, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure and other diseases | TEXAS BIOTECHNOLOGY CORP. | 2003-10-14 | — | — | US | disclosed |
| EP-1342721-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| EP-0946552-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998013366-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208084-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885ALDH1A1 4434/4885 |
| US-20020091272-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885ALDH1A1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.